{"id":10398,"date":"2024-11-13T17:08:08","date_gmt":"2024-11-13T17:08:08","guid":{"rendered":"https:\/\/www.tun.com\/home\/?p=10398"},"modified":"2024-11-13T17:15:48","modified_gmt":"2024-11-13T17:15:48","slug":"potential-breakthrough-biomarker-for-parkinsons-disease-progression-identified","status":"publish","type":"post","link":"https:\/\/www.tun.com\/home\/potential-breakthrough-biomarker-for-parkinsons-disease-progression-identified\/","title":{"rendered":"Potential Breakthrough Biomarker for Parkinson\u2019s Disease Progression Identified"},"content":{"rendered":"\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-uagb-blockquote uagb-block-e7eb3fc3 uagb-blockquote__skin-border uagb-blockquote__stack-img-none\"><blockquote class=\"uagb-blockquote\"><div class=\"uagb-blockquote__content\">Researchers have identified a potential biomarker, ecto-GPR37, that could predict the progression rate of Parkinson\u2019s disease. This discovery promises to revolutionize patient management and treatment approaches.<\/div><footer><div class=\"uagb-blockquote__author-wrap uagb-blockquote__author-at-left\"><\/div><\/footer><\/blockquote><\/div>\n\n\n\n<div class=\"wp-block-group is-content-justification-space-between is-nowrap is-layout-flex wp-container-core-group-is-layout-0dfbf163 wp-block-group-is-layout-flex\"><div style=\"font-size:16px;\" class=\"has-text-align-left wp-block-post-author\"><div class=\"wp-block-post-author__content\"><p class=\"wp-block-post-author__name\">The University Network<\/p><\/div><\/div>\n\n\n<div class=\"wp-block-uagb-social-share uagb-social-share__outer-wrap uagb-social-share__layout-horizontal uagb-block-ee584a31\">\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-ec619ce7\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.facebook.com\/sharer.php?u=\" tabindex=\"0\" role=\"button\" aria-label=\"facebook\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M504 256C504 119 393 8 256 8S8 119 8 256c0 123.8 90.69 226.4 209.3 245V327.7h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.28c-30.8 0-40.41 19.12-40.41 38.73V256h68.78l-11 71.69h-57.78V501C413.3 482.4 504 379.8 504 256z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-32d99934\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/twitter.com\/share?url=\" tabindex=\"0\" role=\"button\" aria-label=\"twitter\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-1d136f14\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.linkedin.com\/shareArticle?url=\" tabindex=\"0\" role=\"button\" aria-label=\"linkedin\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\"><path d=\"M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<p>A new study by a team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a groundbreaking biomarker that could significantly alter the management of Parkinson\u2019s disease. The study, <a href=\"https:\/\/www.nature.com\/articles\/s41531-024-00788-x\" title=\"\">published<\/a> in NPJ Parkinson\u2019s Disease, reveals that levels of a molecule known as ecto-GPR37 in the cerebrospinal fluid are markedly elevated in patients who experience slow progression of Parkinson\u2019s disease.<\/p>\n\n\n\n<p>Parkinson&#8217;s disease is a debilitating neurodegenerative condition characterized by symptoms such as tremors, rigidity, slowness of movement and postural instability. Effective management of the disease varies greatly depending on the rate of progression, making early and precise stratification essential.<\/p>\n\n\n\n<p>\u201cWhat this study suggests is that this biomarker could be used to define whether the progression of the disease will be rapid or slow. At a clinical level, being able to do this stratification is very important because the management of patients with slow-progressing Parkinson\u2019s disease versus those with rapid progression implies a different clinical approach,\u201d Francisco Ciruela, professor at the Faculty of Medicine and Health Sciences at the University of Barcelona and member of the Institute of Neurosciences (UBNeuro) and IDIBELL, said in a <a href=\"https:\/\/idibell.cat\/en\/2024\/11\/researchers-identify-a-potential-biomarker-of-parkinsons-disease-progression\/\" title=\"\">news release<\/a>.<\/p>\n\n\n\n<p>The research team, which includes experts from institutions such as the Spanish National Cancer Research Centre (CNIO), the Karolinska Institute in Sweden and King\u2019s College London, builds on a previous <a href=\"https:\/\/idibell.cat\/2021\/03\/possible-nou-biomarcador-de-la-malaltia-de-parkinson\/\" title=\"\">2021 study<\/a>. In that study, ecto-GPR37 was identified as a potential diagnostic biomarker for Parkinson\u2019s disease. Ecto-GPR37 is a fragment derived from GPR37, a receptor associated with Parkinson&#8217;s, though its exact function and endogenous ligand remain unknown.<\/p>\n\n\n\n<p>To ensure the specificity of ecto-GPR37 to Parkinson\u2019s disease, the researchers analyzed its presence in cerebrospinal fluids from patients suffering not only from Parkinson\u2019s but also from Alzheimer\u2019s and other neurodegenerative diseases like multiple system atrophy and progressive supranuclear palsy. <\/p>\n\n\n\n<p>The results were clear: elevated levels of ecto-GPR37 were found exclusively in patients with slow-progressing Parkinson\u2019s disease, indicating its potential role as a predictor of disease progression.<\/p>\n\n\n\n<p>\u201cThis discovery suggests a possible connection between GPR37 processing\/expression and the speed of disease progression,\u201d added Ciruela. <\/p>\n\n\n\n<p>The differential pattern of GPR37 processing observed in other diseases further underscores its diagnostic potential.<\/p>\n\n\n\n<p>The team is now aiming to validate these promising findings with a larger cohort of patients across multiple hospitals in Europe. The researchers emphasize the need for a multicentre clinical project to confirm the clinical utility and robustness of ecto-GPR37 as a prognostic tool.<\/p>\n\n\n\n<p>Ciruela stressed the significance of the next steps, adding, \u201cTherefore, the next step now would be to develop and launch a multicenter clinical project at European level that allows us to carry out the validation study with Parkinson\u2019s patients, necessary to be able to move towards its clinical application.\u201d<\/p>\n\n\n\n<p>Moreover, thanks to funding from the Michael J. Fox Foundation, the researchers have developed an assay to detect ecto-GPR37 in blood samples, making the biomarker easier to analyze and potentially more accessible.<\/p>\n\n\n\n<p>The discovery of ecto-GPR37 as a biomarker for Parkinson&#8217;s disease progression could pave the way for treatment plans, improving the quality of life for those affected by this challenging condition.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study by a team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a groundbreaking biomarker that could significantly alter the management of Parkinson\u2019s disease. The study, published in NPJ Parkinson\u2019s Disease, reveals that levels of a molecule known as ecto-GPR37 in the cerebrospinal fluid are [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"single-no-separators","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-10398","post","type-post","status-publish","format-standard","hentry","category-health"],"acf":[],"aioseo_notices":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"The University Network","author_link":"https:\/\/www.tun.com\/home\/author\/funky_junkie\/"},"uagb_comment_info":0,"uagb_excerpt":"A new study by a team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a groundbreaking biomarker that could significantly alter the management of Parkinson\u2019s disease. The study, published in NPJ Parkinson\u2019s Disease, reveals that levels of a molecule known as ecto-GPR37 in the cerebrospinal fluid are&hellip;","_links":{"self":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/10398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/comments?post=10398"}],"version-history":[{"count":8,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/10398\/revisions"}],"predecessor-version":[{"id":10431,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/10398\/revisions\/10431"}],"wp:attachment":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/media?parent=10398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/categories?post=10398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/tags?post=10398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}